Moleculin Biotech, Inc. — Director's Dealing 2019

Jul 15, 2019

SEC Form 4/A — Form 4/A

Issuer: Moleculin Biotech, Inc. (MBRX)
CIK: 0001659617
Period of Report: 2018-06-06

Reporting Person: KLEMP WALTER V (Director, CEO and President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-06	Stock option (right to buy)	$1.82	A	500000	Acquired	2028-06-06	Common Stock (500000.0)	Direct

Footnotes

F1: As previously reported on a Form 4 filed on June 8, 2018 by the reporting person, the reporting person reported acquiring stock options to purchase 603,000 shares of common stock. However, the Company subsequently determined that stock options to purchase 103,000 shares of common stock under the Company's 2015 Stock Plan were not validly granted pursuant to the plan because they exceeded the limit on the number of stock options that may be granted to any individual participant one year period. Accordingly, the attempted grant of these excess stock options was ineffective, and they were never granted to the reporting person. The reporting person is filing this amendment to report the correct amount of stock options acquired, and to revise the vesting schedule for the stock options to provide that 150,750 options vested as of June 6, 2019, and the remaining options shall vest in three equal installments on June 6, 2020, 2021, and 2022.

F2: Issued in connection with the reporting person's employment with the Company.